Actively Recruiting
A Study to Assess the Adverse Events and How Oral ABBV-1042 Moves Through the Body of Healthy Adult Participants
Led by AbbVie · Updated on 2025-10-30
48
Participants Needed
1
Research Sites
26 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study will assess the adverse events, tolerability, and how oral ascending doses of ABBV-1042 moves through the body of healthy adult participants.
CONDITIONS
Official Title
A Study to Assess the Adverse Events and How Oral ABBV-1042 Moves Through the Body of Healthy Adult Participants
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Body mass index (BMI) between 18.0 and 32.0 kg/m2 at screening
- Body weight at least 45 kg at screening and initial confinement
- General good health based on medical history, physical exam, vital signs, lab tests, and a 12-lead ECG
You will not qualify if you...
- History of suicidal thoughts within 1 year or suicidal behavior/self-injury within 2 years before treatment
- Significant cardiovascular, pulmonary, gastrointestinal, renal, hepatic, metabolic, genitourinary, endocrine, cancer, blood, immune, neurological, or psychiatric disease that may affect safety or trial results
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Acpru /Id# 279405
Grayslake, Illinois, United States, 60030
Actively Recruiting
Research Team
A
ABBVIE CALL CENTER
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
TRIPLE
Allocation
RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
BASIC_SCIENCE
Number of Arms
6
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here